AlphAIalphai — Financial news for AI agents
Stock TitanAPR 12 min read$QNRX

Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades

Stonepine Capital Management, LLC, a ten percent owner of Quoin Pharmaceuticals, Ltd. (QNRX), has filed a Form 4 with the SEC, indicating no reported purchases, sales, or other share transactions. The filing notes that due to a change in outstanding shares, Stonepine Capital now beneficially owns less than 10% of Quoin Pharmaceuticals' outstanding ordinary shares, despite being classified as a 10% owner on the form. This Form 4 suggests a neutral impact on sentiment as it reports no new trading activity.

Original reporting
Stock Titan
Published Apr 1, 2026, 3:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 3:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades — source image
Source · Stock Titan
Decision brief

The 30-second read

$QNRXNeutralLow
01

Why it matters

The filing indicates no insider trading activity, suggesting stability in insider sentiment.

02

Market read

The event has limited relevance to market dynamics, given the absence of trading activity and minor ownership change.

03

What to watch

Potential undisclosed private transactions or strategic decisions not captured in Form 4 filings.

Timing: low

Background

Stonepine Capital's ownership stake decreased below 10% due to share changes, but no trading occurred.

Company-level read

Ticker impact

$QNRXNeutralHigh confidence
Context

The filing indicates no recent trading activity by Stonepine Capital, a significant shareholder, which suggests a neutral stance or lack of new information affecting the stock.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

The absence of trading activity and the reduction below 10% ownership indicate no new insider buying or selling, leading to a neutral outlook.

Market effects

Sector

Limited impact on the biotech or life sciences sector; no change in sector sentiment.

Regional

Minimal regional market influence due to the company's niche focus.

Global

Negligible; the event is company-specific and does not affect global markets.

Counterpoint

What could challenge this read

Some traders might interpret the lack of activity as a sign of potential upcoming insider moves, but current evidence suggests neutrality.

Key entities

  • Institutional Investor
    Stonepine Capital Management, LLC

    A significant shareholder of Quoin Pharmaceuticals, Ltd.

  • Company
    Quoin Pharmaceuticals, Ltd.

    The issuer of the securities in question.

Read at source← All news

Related articles

JUL 10
$QNRXMedAI 8/10

FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial

Quoin Pharmaceuticals said the FDA cleared its IND for QRX003 to start a Phase II trial for Peeling Skin Syndrome. The study is expected to begin in 2H 2026, enrolling 6 to 8 patients in the US and Europe. Patients will apply the topical lotion twice daily to over 80% of body surface for 52 weeks. Quoin targets approval in 2028.

yahoo.com3 min
JUN 3
$QNRXMedAI 9/10

Quoin Files IND For QRX003 To FDA In Treatment Of Peeling Skin Syndrome

Quoin Pharmaceuticals said it filed an IND with the FDA for QRX003 to treat Peeling Skin Syndrome, based on results from an ongoing investigator-led pediatric study. The company expects to start a Phase 2 trial in the second half of 2026 after FDA review. It reported improvements in skin, sleep and quality of life, and said QRX003 was well tolerated.

rttnews.com4 min
AUG 8
$NOKMed

Nokia’s (NOK) AI Network Bet Gets A Taiwan Proving Ground

Nokia (NOK) said it signed a 5G expansion agreement with Taiwan Mobile on July 14 to deploy its AirScale portfolio and AI-driven network software. The deal covers four AI applications, including predictive analytics, SON automation, baseband and radio upgrades, energy management, and self-healing. Nokia cites Aetha data on AI traffic growth and expects AI-RAN spectral efficiency to rise from 20% to 50% next year and 100% by 2028.

yahoo.com4 min